Roche increased sales by two percent to CHF 45.9 billion in the first three quarters of 2025. Growth was driven by sustained high demand for newly developed medicines for the treatment of serious diseases and innovative diagnostic solutions. This more than offset sales declines due to the expiry of patents on older medicines and the impact of health policy measures in China.
Roche focuses on serious diseases and pioneering research
Thomas Schinecker, CEO of Roche, commented on the quarterly results: "We continue to build on our positive momentum with strong sales growth of seven percent at constant exchange rates. Our momentum is further reflected in our pipeline with a number of positive clinical read-outs and a record ten potentially transformative medicines progressing into the final phase of development for diseases with significant unmet need. By the end of the decade, we expect phase III clinical results for up to 19 new medicines. Our groundbreaking next-generation sequencing technology, set to launch next year, has achieved a new record for decoding a whole human genome in under four hours. Based on our strong results, we are raising our earnings outlook for the full year.”
The company made particular progress in the development of drugs for neurodegenerative diseases such as Alzheimer's, various cancers, hemophilia, and metabolic and autoimmune diseases. In obesity research, too, new drug candidates were advanced to late-stage development.
Roche reports strong growth in North America, Europe, and Asia
Sale in the Pharmaceuticals Division rose by four percent to CHF 35.6 billion. New drugs for the treatment of serious diseases such as breast cancer, allergic asthma, hemophilia, eye diseases, and multiple sclerosis generated total growth of around CHF 2.4 billion. Together, they offset declining revenues due to biosimilar competition.
The US market performed particularly well, with sale growth of eight percent after adjusting for currency effects. Sales in Europe and Japan each rose by five percent. In the International region, growth was 13 percent, mainly due to strong growth in China. Converted into Swiss Francs, sales in the US, Europe and Japan each rose by three percent, and in the International region by five percent.
Stable diagnostics business despite political conditions
The Diagnostics Division achieved a slight currency-adjusted sales increase of one percent to CHF 10.3 billion. Growth in Europe, North America, and Latin America offset the impact of Chinese price reforms. Solutions in molecular and pathology diagnostics were particularly in demand.
Roche confirms outlook for full year
Roche expects currency-adjusted sales growth in the mid-single-digit range for the full year 2025. The dividend is also expected to increase again.
